> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lifestyle interventions show no clear effect on epigenetic clocks in randomised trials
- URL: https://www.coios.me/lifestyle-interventions-show-no-clear-effect-on-epigenetic/
- Published: 2026-11-18T13:25:18.000Z
- Updated: 2026-11-18T13:53:23.000Z
- Description: Eight randomised trials in 1,675 middle-aged and older adults showed no significant effect of lifestyle interventions on DNA methylation clocks.
- Author: Daniel Ryan
- Tags: Tomorrow's world, Slowing ageing itself, Diet, exercise and sleep, World, #peer-reviewed, #contradicts, #item, #source-2026-11, #score-85

This systematic review and meta-analysis asked whether lifestyle interventions slow DNA methylation (DNAm) ageing. It pooled eight randomised controlled trials of exercise, diet, caloric restriction or multidomain programmes in 1,675 adults. Trials had a mean age of 45 or over, and effects were pooled separately for three clock types. No significant effect appeared for chronological-age clocks (SMD -0.04), phenotypic/mortality clocks (-0.17) or DunedinPACE (-0.01). The two largest trials were centred on the null, while favourable estimates came from smaller trials. Certainty was rated low to very low, and a small effect on phenotypic/mortality clocks cannot be excluded.

*Why it is interesting: DNA methylation clocks are widely used as surrogate endpoints for biological ageing. This review pools the randomised evidence and finds the largest trials centred on no effect.*

Source

[Archives of Gerontology and Geriatrics, 16 November 2026](https://doi.org/10.1016/j.archger.2026.106484?ref=coios.me)

Paper

Do lifestyle interventions slow epigenetic aging in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials

Authors

Sanchez K, Sánchez Herrera S

DOI

10.1016/j.archger.2026.106484

Type

Peer-reviewed article

Design

Prospectively registered systematic review and three-level meta-analysis of 9 RCTs (8 pooled; 1,675 participants, 27 clock-level estimates) in adults aged ≥45, searches to October 2026

Verdict

Contradicts prior evidence

Driver

[Slowing ageing itself](https://www.coios.me/d-ageing/)

Driver

[Diet, exercise and sleep](https://www.coios.me/d-diet-activity/)

Abstract — the authors' own words, CC BY

Background

DNA methylation (DNAm) clocks are used as surrogate endpoints of biological aging, but randomized evidence that lifestyle interventions slow DNAm-based aging in middle-aged and older adults is lacking. Methods

In this prospectively registered systematic review (PRISMA 2020), we searched PubMed/MEDLINE, Web of Science, Scopus and CENTRAL (24 September 2026), two trial registers and citations of included trials (20 October 2026) for randomized controlled trials (RCTs) of lifestyle interventions (exercise, diet, caloric restriction, multidomain) in adults with mean age ≥45 years reporting a validated DNAm clock. Because clocks capture distinct constructs, standardized mean differences (SMD; negative = slower aging) were pooled separately for chronological-age clocks, phenotypic/mortality clocks and pace of aging, using three-level models with cluster-robust inference; certainty was rated with GRADE. Results

Nine RCTs were included and eight (1675 participants; 27 clock-level estimates) were pooled. No statistically significant effect was found for chronological-age clocks (SMD -0.04, 95% CI -0.31 to 0.24), phenotypic/mortality clocks (-0.17, -0.42 to 0.09) or DunedinPACE (-0.01, -0.17 to 0.15). The two largest trials were centred on the null (-0.01, -0.06 to 0.04); favourable estimates came from smaller trials. Results were consistent across sensitivity analyses, including one clock per trial (-0.26, -0.57 to 0.06). Certainty was low to very low. Conclusions

Randomized evidence does not demonstrate a statistically significant effect of lifestyle interventions on DNAm-based measures of aging in middle-aged and older adults; a small effect on phenotypic/mortality clocks cannot be excluded. Adequately powered trials with a pre-specified primary clock and standardized reporting are needed.